Lyra Therapeutics Announces FDA Clearance of Investigational New Drug Application for Phase 2 Trial of LYR-210 for Chronic Rhinosinusitis

Lyra Therapeutics announced the U.S. FDA has cleared the company’s Investigational New Drug (IND) application for LYR-210 for the treatment of chronic rhinosinusitis (CRS). Lyra plans to incorporate U.S. clinical sites into LANTERN, its ongoing global Phase 2 clinical...

Pin It on Pinterest